Premium
Alpha‐amylase as molecular target for treatment of diabetes mellitus: A comprehensive review
Author(s) -
Kaur Navjot,
Kumar Vanktesh,
Nayak Surendra Kumar,
Wadhwa Pankaj,
Kaur Paranjit,
Sahu Sanjeev Kumar
Publication year - 2021
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13909
Subject(s) - acarbose , postprandial , chemistry , maltose , enzyme , indole test , biochemistry , hydrazone , pharmacology , alpha amylase , amylase , diabetes mellitus , endocrinology , stereochemistry , medicine
The alpha (α)‐amylase is a calcium metalloenzyme that aids digestion by breaking down polysaccharide molecules into smaller ones such as glucose and maltose. In addition, the enzyme causes postprandial hyperglycaemia and blood glucose levels to rise. α‐Amylase is a well‐known therapeutic target for the treatment and maintenance of postprandial blood glucose elevations. Various enzymatic inhibitors, such as acarbose, miglitol and voglibose, have been found to be effective in targeting this enzyme, prompting researchers to express an interest in developing potent alpha‐amylase inhibitor molecules. The review mainly focused on designing different derivatives of drug molecules such as benzofuran hydrazone, indole hydrazone, spiroindolone, benzotriazoles, 1,3‐diaryl‐3‐(arylamino) propan‐1‐one, oxadiazole and flavonoids along with their target–receptor interactions, IC 50 values and other biological activities.